Hydrocodone/paracetamol - Acura Pharmaceuticals

Drug Profile

Hydrocodone/paracetamol - Acura Pharmaceuticals

Alternative Names: Acetaminophen/hydrocodone; Acetaminophen/hydrocodone bitartrate; Aversion H&A; Hydrocodone bitartrate/acetaminophen; Hydrocodone bitartrate/paracetamol; Hydrocodone/acetaminophen; LTX 03; Paracetamol/hydrocodone; Paracetamol/hydrocodone bitartrate; Vycavert Tablets

Latest Information Update: 14 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acura Pharmaceuticals
  • Class Acetanilides; Morphine derivatives; Non-opioid analgesics; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Pain

Most Recent Events

  • 09 Oct 2017 Acura Pharmaceuticals plans a second buffer dose ranging clinical trial for Pain in the fourth quarter of 2017
  • 02 Oct 2017 Top-line pharmacokinetics data from a clinical (Study 300) trial in Pain released by Acura Pharmaceuticals
  • 02 Oct 2017 Acura Pharmaceuticals initiates a clinical (Study 300) trial for Pain in USA before October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top